

## FACULTY

**Laura Amato**, Department of Epidemiology for regional Lazio Health Service (Italy)

**Mireille Broeders**, Department for Health Evidence, Radboud University Medical Centre – Nijmegen (Netherlands)

**Carla Cogo**, Oncological Institute of Veneto (IRCCS) Padova (Italy)

**Rosanna D'Antona**, Europa Donna - Italy

**Fabrizio Faggiano**, University of Eastern Piedmont Novara, Italian Association of Epidemiology (AIE) (Italy)

**Alfonso Frigerio**, Unit of Epidemiology – CPO Piedmont –Turin (Italy)

**Livia Giordano**, Unit of Epidemiology – CPO Piedmont –Turin (Italy)

**Paolo Giorgi Rossi**, Organisational Unit of Epidemiology and Risk Communication – Reggio Emilia (Italy)

**Roberto Grilli**, ARS Emilia Romagna region (Italy)

**Solveig Hofvind**, Cancer Registry of Norway (Norway)

**Karsten Juhl Jørgensen**, Nordic Cochrane Centre – Copenhagen (DK)

**Manuela Lerda**, Italian Society of General Medicine (Italy)

**Silvia Minozzi**, Department of Epidemiology for regional Lazio Health Service (Italy)

**Paola Mosconi**, Institute for Pharmacological Research "Mario Negri" / Partecipasalute, (Italy)

**Sue Moss**, Queen Mary University of London Wolfson Institute (UK)

**Carlo Naldoni**, Department of Public Health Emilia Romagna region (Italy)

**Nick Ormiston-Smith**, Cancer Research UK Member of the Secretariat for the Independent UK Panel on Breast Cancer Screening (UK)

**Eugenio Paci**, Clinical and Descriptive Epidemiology Unit, ISPO -Cancer Prevention and Research Institute, Florence (Italy)

**Pietro Panizza**, National Institute of Cancer Institute - Milan (Italy)

**Antonio Ponti**, Unit of Epidemiology – CPO Piedmont –Turin (Italy)

**Amanda Ramirez**, King's Health

Partners College London (UK)

**Carlo Saitto**, Local Health Unit Roma E (Italy)

**Anna Sapino**, Department of Molecular Biotechnology and Health Sciences University of Turin (Italy)

**Nereo Segnan**, Unit of Epidemiology – CPO Piedmont –Turin (Italy)

**Robert Smith**, American Cancer Society - USA

**Corrado Tinterri**, Clinical Institute Humanitas – Rozzano (Italy)

**Marco Zappa**, Clinical and Descriptive Epidemiology Unit, ISPO - Cancer Prevention and Research Institute, Florence (Italy)

### Registration

It is due no entry fee. Participation is limited to the first 100 people who send the registration form duly completed to the Organizing Secretariat no later than January 20, 2014.

The registration form is available on the websites:

[www.osservatorionazionale screening.it](http://www.osservatorionazionale screening.it)

[www.gisma.it](http://www.gisma.it)

### To get to the venue

#### by car

from Ancona and from Milan, continue to Highway Exit "Fiera"

#### by train

take bus number 35 or 38

#### walk 20 minutes

### Organizing Secretary



Palazzo Capponi - Via Giusti, 52

50121 Firenze

Tel 055 4630555 - Fax 055 476824

[congressi@wwes.it](mailto:congressi@wwes.it)

[susanna.casprini@wwes.it](mailto:susanna.casprini@wwes.it)

[simona.lumachelli@wwes.it](mailto:simona.lumachelli@wwes.it)



ISTITUTO PER LO STUDIO  
E LA PREVENZIONE ONCOLOGICA



The Italian Group for Mammography Screening (GISMa) and the National Screening Monitoring Centre (ONS) in cooperation with the Italian Cochrane Centre, the Italian Association of Epidemiology, Partecipasalute, SIRM, EUROPA DONNA and SIMG organise the workshop:

## European estimates of the mammography screening balance sheet of benefits and harms: challenges for communication and research

**Bologna, 30 January 2014**

**Regione Emilia e Romagna  
Aula Magna - Viale Aldo Moro, 30**

*In 2012, the publication by the Euroscreen Working Group of the balance sheet of benefits and harms of service screening programmes based on the review of the outcomes of European observational studies and the report of the UK Independent Panel on the National Health Service screening program renewed the interest for the mammography controversy.*

*The conclusion of the UK Independent Panel was service screening should continue but communication of benefit and harms of screening is warranted. In this workshop we would like to review the evidence on breast cancer screening outcomes, discuss results of the balance sheet of benefits and harms and methodological problems in the evaluation of screening outcomes. The aim is to establish the state of knowledge and how to move towards a better communication of the facts to women and stakeholders and the implications for future challenges in Europe.*

**MORNING**

10.00 *Apertura dei lavori* *C. Lusenti*  
 10.15 *Introduction* *M. Zappa, L. Giordano*

**10.30 The screening mammography controversy****Chairs: L. Amato, C. Naldoni**

10.30-10.55 A comparison of the mammography screening reviews and the Guideline debate in US *R. Smith*

10.55-11.20 The state of the controversy and the UK Panel Independent Review *N. Ormiston-Smith*

11.20-11.45 A perspective on screening mammography programs impact in Europe *K. Jørgensen*

11.45-12.05 Issues in mortality trends evaluation *S. Moss*

12.05-12.30 The Euroscreen review of observational studies *E. Paci*

12.30- 13.00 *Discussion* *F. Faggiano, S. Minozzi*

**13.00 Lunch****AFTERNOON****14.00 Communication of the outcomes: experiences from Europe****Chairs: R. D'Antona, C. Cogo**

14.00-14.30 Offering informed choice about breast cancer screening: The English Experience *A. Ramirez*

14.30-14.40 Breast cancer screening experiences on communication from: The Netherland *M. Broeders*

14.40-14.50 Norway *S. Hofvind*

14.50-15.00 Italy *L. Giordano*

15.00-15-20 *Discussion* *P. Mosconi, M Lerda*

**15.20 Overdiagnosis, overtreatment and false positive results****Chairs: A. Ponti, P. Panizza**

15.20-15.40 Overdiagnosis and overtreatment: definitions and problems for health services *C. Saitto*

15.40-16.00 Overdiagnosis and overtreatment: how to face them? *N. Segnan*

16.00-16.15 A comparison of the overdiagnosis estimates in prostate and breast screening *M. Zappa*

16.15-16.35 Estimates of lifetime risk of false positive results *S. Hofvind*

16.35-17.00 *Discussion* *E. Paci, A. Frigerio, C. Tinterri*

**17.00 Future challenges for breast cancer research****Chairs: S. Moss, R. Grilli**

17.00-17.20 Towards Horizon 2020: tailored screening as a research challenge *M. Broeders*

17.20-17.45 *Discussion* *A. Sapino, P. Giorgi Rossi*

**17.45 Conclusion**

The GISMA-ONS statement and future plans *L. Giordano, E. Paci*

**18.00 End of the Workshop**

